---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-240991"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2022-09-08T23:59:59+00:00"
generated_at: "2026-06-23T12:56:38.657358+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Homology Medicines appoints Albert Seymour as CEO; Arthur Tzianabos named Chairman

## Summary
- Albert Seymour, former CSO and President, promoted to CEO; base salary raised to $570,000, bonus target 55%.
- Seymour received option for 23,000 shares at $2.18 and 14,000 RSUs, vesting over 48 months and 3 years.
- Arthur Tzianabos resigned as CEO, appointed Chairman of Board; consulting agreement pays $26,571/month through March 31, 2023.
- Kush Parmar resigned from Board and Chairman role; Jeffrey Poulton appointed Lead Director.
- CFO W. Bradford Smith's severance amended: 12 months base salary continuation on qualifying termination.

## SEC filing metadata
- accession: 0001193125-22-240991
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2022-09-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/d403635d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-240991
- JSON: https://secwatch.observer/filing/0001193125-22-240991.json
- Plain text: https://secwatch.observer/filing/0001193125-22-240991.txt

## Key facts
- Executive change
  Albert Seymour was appointed as Class II Director at Q32 Bio Inc..
  - Action: appointed
  - Role: Class II Director
  source text: Also on September 6, 2022, the Board appointed Albert Seymour, Ph.D. as a Class II director of the Company, replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm
- Executive change
  Jeffrey V. Poulton was appointed as Lead Director at Q32 Bio Inc..
  - Action: appointed
  - Role: Lead Director
  source text: and has also appointed Jeffrey V. Poulton to serve as the Lead Director of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm
- Executive change
  Arthur O. Tzianabos was appointed as Chairman of the Board at Q32 Bio Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: The Board has appointed Arthur O. Tzianabos, Ph.D. to replace Dr. Parmar as the Chairman of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm
- Executive change
  Arthur O. Tzianabos resigned as Chief Executive Officer at Q32 Bio Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On September 6, 2022, in connection with Dr. Seymour’s promotion, Dr. Tzianabos notified the Company of his resignation as Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm
- Executive change
  Albert Seymour was appointed as Chief Executive Officer at Q32 Bio Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On September 6, 2022, the Board of Directors (the “ Board ”) of Homology Medicines, Inc. (the “ Company ”) appointed Albert Seymour, Ph.D., the Company’s former Chief Scientific Officer and President, to serve as the Company’s Chief Executive Officer, in addition to his role as the Company’s President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm
- Executive change
  Kush M. Parmar resigned as Chairman of the Board at Q32 Bio Inc..
  - Action: resigned
  - Role: Chairman of the Board
  source text: Also on September 6, 2022, the Board appointed Albert Seymour, Ph.D. as a Class II director of the Company, replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.